FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingt

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	_	_		 _	
ton, D.C. 2054	9				OMB APPROVAL

ı	OMB Number:	3235-0287
ı	Estimated average burde	en
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Oakes Gregory					2. Issuer Name and Ticker or Trading Symbol Landos Biopharma, Inc. [LABP]									k all applica	10% Owner			
(Last) (First) (Middle) C/O LANDOS BIOPHARMA, INC. PO BOX 11239					3. Date of Earliest Transaction (Month/Day/Year) 02/28/2023								X	Officer (give title Other (spe below) Chief Executive Officer				pecify
(Street) BLACKSBURG VA 24062 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Transaction ate Ionth/Day/	Execution Date,		Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 a			5. Amoun Securities Beneficial Owned Fo Reported	Form (D) of the collowing (I) (In		Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	mount (A) or (D)		ice	Transaction	unsaction(s) str. 3 and 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Da urity or Exercise (Month/Day/Year) if any		Execution Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	ode V (A) (D) Expiration Date Title Title Amount or Number of Shares						(Instr. 4)							
Employee Stock Option (right to buy)	\$0.37	02/28/2023		A		475,300		(1)	02	2/27/2033	Common Stock	475,3	300	\$0.00	475,30	00	D	

Explanation of Responses:

1. 1/4th of the shares initially subject to the option shall vest on the one (1) year anniversary of the date of grant (such anniversary being the "Anniversary Date") and 1/48th of the shares initially subject to the option shall vest on each monthly anniversary of the Anniversary Date thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.

Remarks:

03/02/2023 /s/ Gregory Oakes

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.